LifeMD (LFMD) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
7 May, 2026Platform scale and care delivery
Over 453 million platform interactions and 365,000+ active patients, with 1.95 million unique monthly website visitors.
End-to-end care platform supports both synchronous and asynchronous visits across primary and specialty care.
Integrated medical and pharmacy benefits expand patient access, reduce costs, and improve adherence.
Nationwide affiliated medical group delivers consistent, high-quality care across 50 states.
Platform proven to deliver complex virtual care at scale for over 200 conditions.
AI and technology infrastructure
AI tools augment clinicians, increasing throughput and consistency in diagnosis and treatment.
AI clinical decision support tool launching in Q2 2026, connecting to patient records for efficient, auditable care.
AI agents support pre-consult data collection, consult transcription, scheduling, and revenue cycle management.
Proprietary technology stack and large, structured patient database create a durable AI advantage.
Internal AI leadership and third-party partnerships drive advanced AI deployment.
Pharmacy and benefits infrastructure
Fully licensed 50-state pharmacy with direct integration to the virtual care platform.
Strategic collaborations with Eli Lilly, Novo Nordisk, and HRT Club for GLP-1 and hormonal health.
AI-enabled 503-A compounding licensure across 35 states, expanding to all 50 by year-end.
Nationwide benefits infrastructure covers 112M lives today, expanding to 230M+ by Q2 2026.
Real-time benefit verification, prior authorization, and claims management enhance access and affordability.
Latest events from LifeMD
- Q2 2026 revenue was $47.3M, gross margin 89%, and active subscribers grew 20%.LFMD
Q2 2026 - Virtual care platform drives growth in GLP-1, women's health, and specialty care with strong margins.LFMD
16th Annual LD Micro Invitational Conference - Q1 2026 delivered record subscriber growth, 88% gross margin, and reaffirmed full-year guidance.LFMD
Q1 2026 - Key votes include director elections, auditor ratification, and a significant equity plan amendment.LFMD
Proxy filing - Record patient growth and revenue, with durable expansion in virtual care and pharma partnerships.LFMD
Proxy filing - Shareholders will vote virtually on directors, auditor ratification, and an updated equity plan.LFMD
Proxy filing - Record revenue growth, expanding margins, and strong cash position drive 2026 outlook.LFMD
Q4 2025 - Telehealth revenue rose 67% year-over-year, driving profitability and strong margin expansion.LFMD
Q2 2024 - Record Q4 revenue and EBITDA growth, with strong 2025 outlook and margin recovery expected.LFMD
Q4 2024